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ReviewZebrafish-Based
Small Molecule Discovery
power of whole organism, phenotype-based compound
discovery, practical and ethical factors have limited the
overall utility of the approach. The examples above in-
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Massachusetts General Hospital volved unplanned exposures of cattle, sheep, and hu-
mans to small molecules, followed by astute observationCharlestown, Massachusetts 02129
of the results. Planned, systematic exposure of mam-
mals to uncharacterized small molecules for the purpose
of compound discovery would be expensive, laborious,The earliest examples of small molecule discovery in-
require large quantities of the chemical compounds, andvolved serendipitous phenotypic observations in whole
could potentially raise ethical questions.organisms, but this organism-based process has given
To accelerate small molecule discovery, some at-way in recent decades to systematic, high-throughput
tempts to systematize whole-organism chemical screen-assays using purified proteins, cells, or cell extracts.
ing were made. In 1907, Paul Ehrlich tested 900 arsenicalIn vitro screens have been successful at identifying
compounds on mice infected with trypanosomes [4].modifiers of well-understood biological processes,
Although unsuccessful, these experiments laid the ground-but they are limited in their ability to discover modifiers
work for the eventual discovery of the syphilis treatmentof processes that are poorly understood or occur only
Salvarsan. In the 1950s, Squibb Co. discovered the anti-in an integrated physiological context. Small model
tuberculosis drug isoniazid after exposing mice to moreorganisms, especially the zebrafish, make it possible
than 5000 compounds (and purportedly killing more thanto combine the advantages of organism-based small
50,000 mice in the process) [5]. Therefore, despite amolecule discovery with the technologies and through-
few notable successes, the benefits of whole-organism,put of modern screening. The combination of model
phenotype-based small molecule discovery have beenorganisms with high-throughput screening is likely to
overshadowed by the practical limitations of the ap-extend small molecule discovery efforts to fields of
proach.study such as developmental biology and to broaden
During the last three decades, small molecule discov-the range of diseases for which drug screening can
ery has moved from organism-based to target-basedbe performed.
discovery. In target-based discovery, a target protein is
identified, purified, and used for in vitro screening to
Introduction identify inhibitors of its biochemical activity. This target-
Organism-based approaches to small molecule discov- based approach has made compound discovery more
ery are not new. Prior to advances in in vitro screening in systematic, automated, and able to capitalize on the
the 1970s, a significant proportion of biologically active burgeoning data generated by molecular and medical
small molecules were discovered based on their interac- research. A number of outstanding successes have re-
tions with whole organisms. Often, serendipitous expo- sulted, including the discovery of HIV protease inhibitors
sure of animals to naturally occurring small molecules and, more recently, the c-Abl kinase inhibitor Gleevec.
resulted in interesting (or terrifying) phenotypes, leading
ultimately to characterization of the causative molecules.
For example, dicumarol was discovered in the 1930s The Benefits of Organism-Based
when cattle in the northern United States began dying Small Molecule Discovery
inexplicably of internal bleeding after having fed on rot- The ascendance of in vitro, target-based approaches
ting sweet clover [1]. A group of researchers from the has made compound discovery systematic and rational,
University of Wisconsin identified the causative agent as but several important advantages of organism-based
dicumarol, which with its derivatives remains the most discovery have been sacrificed (Figure 1). First, while
frequently prescribed anticoagulant today. More recently, organism-based discovery can identify chemical modifi-
observation of cyclopia and other developmental defects ers of virtually any biological process, modern target-
in sheep exposed to Veratrum californicum led to dis- based approaches typically only discover modifiers of
covery of the smoothened antagonist cyclopamine [2]. well-understood processes. Because target-based ap-
More than any other animal, humans have been the proaches are dependent upon a priori selection of a
subjects for such serendipitous small molecule discov- protein target, they are biased toward discovery of small
eries. In 1776, William Withering observed the beneficial molecule inhibitors of well-known proteins. As a result,
effects of the foxglove plant on a woman suffering from this approach is less likely to reveal the functions of
heart failure. From the foxglove he isolated digitalis, novel targets and provide novel fundamental insights
which is still an important therapy for heart failure [3]. into poorly understood phenomena. Biological under-
Analgesics, antiinflammatories, antifungals, and of course standing is a prerequisite, not a result, of target-based
many psychoactive compounds have been discovered approaches. Despite the thousands of potential small
by human exposure to small molecules. molecule targets identified by the human genome proj-
Although the examples listed above illustrate the ect, it remains difficult to predict which proteins must
be targeted to reverse a disease phenotype or to alter
a poorly understood organismal process. Consequently,*Correspondence: peterson@cvrc.mgh.harvard.edu
Chemistry & Biology
902
Figure 1. Organism- versus Target-Based
Small Molecule Discovery
Target-based discovery, such as discovery
of cox-2 inhibitors (top), begins with selection
of a molecular target, followed by screening
for chemical modifiers of the target’s activity.
The true biological effect (phenotype) is only
determined at the end of the process when
efficacy and safety are tested in animals and
man. In contrast, organism-based discovery
begins with detection of desirable pheno-
types in whole organisms and may lead to
discovery of novel targets. For example, the
discovery of dicumarol began as an observa-
tion of hemorrhaging in cattle and proceded
to identification of vitamin K epoxide reduc-
tase as its target (bottom).
target-based approaches continue to identify small mol- Zebrafish as a Model Organism
The zebrafish is rapidly gaining popularity as a modelecule modulators of a relatively small group of targets,
organism for developmental biology and geneticswhile novel therapeutic targets await validation by other
[7–10]. The attributes that have made the zebrafish suchmeans. Moreover, fields of study such as developmental
a powerful model for genetic screening also make it wellbiology receive little benefit from the discovery of new
suited for small molecule screening. First, unlike the fruitmolecules. Like other chemical genetic screens [6], or-
fly, round worm, baker’s yeast, or other popular geneticganismal screens permit discovery of new pathways and
model organisms, the zebrafish is a vertebrate. It pos-targets, but they also expand the range of observable
sesses discrete organs and tissues such as a brain,phenotypes to include those affecting development,
sensory organs, heart, liver, pancreas, kidneys, intes-physiology, and behavior.
tines, bones, muscles, etc. (Figure 2A). Zebrafish organsThe second advantage of using whole organisms for
are remarkably similar to their human counterparts atcompound discovery is the physiological context they
the anatomical, physiological, and molecular levels, fa-provide. Target-based discovery is usually performed
cilitating study of vertebrate biological processes thatusing purified proteins, tissue culture cells, or cell ex-
are inaccessible using invertebrate model organisms.tracts in in vitro assays. Small molecules discovered in
The zebrafish is also small for a vertebrate. Adultsthis in vitro context may have unexpected activity in
reach 3 cm in length, but during the embryonic and larvalan in vivo context. Initial hits must be tested further
stages of life, the zebrafish is only about 1–2 mm long.in animals for effectiveness, side effects, toxicity, and
During these stages, developing fish can live for dayspharmacokinetic/pharmacodynamic profile. The vast
in a single well of a standard 384-well plate, survivingmajority of small molecules discovered by in vitro target-
on nutrients stored in their yolk sacs (Figure 2B). Zebra-based screening exhibit undesirable characteristics
fish are simple and inexpensive to raise, and a single(such as lack of specificity or toxicity) when tested in
pair of adults can routinely lay hundreds of fertilizedthe context of a whole organism. In contrast, a small
eggs in a single morning. Consequently, even a smallmolecule discovered by virtue of its ability to cause a
zebrafish facility can generate many thousands of em-desirable phenotype in a whole organism is more likely
bryos per day, making it possible to efficiently screento be cell permeable, devoid of obvious toxicities, effec-
large libraries of molecules.
tive, with an acceptable pharmacokinetic/pharmacody-
Another notable attribute of the zebrafish is the trans-
namic profile. Efficacy and specificity in an organismal
parency of its embryos. Every internal organ and struc-
context is the standard that small molecules ultimately ture can be visualized in the intact, living organism, obvi-
seek to meet. Moving the organism to the initial stages ating the need to sacrifice or dissect the animal and
of compound discovery combines screening and animal permitting multiple observations of dynamic processes.
testing into one step. In contrast, observing organ development in the devel-
Recently, a number of groups have attempted to com- oping mouse typically requires sacrificing the mother,
bine the advantages of organism-based small molecule followed by dissection of the embryo. The optical clarity
discovery with the technologies of modern high-through- of the zebrafish embryo becomes even more useful
put screening. Small model organisms including Caeno- when combined with fluorescent markers that highlight
rhabditis elegans, Drosophila melanogaster, Arabidop- the locations or activities of specific populations of cells
sis thaliana, and the zebrafish Danio rerio are all small (Figure 2C). For example, dozens of transgenic zebrafish
enough to grow in microformat screening plates. Among lines have been created that express fluorescent pro-
these organisms, the zebrafish is most closely related teins in locations ranging from the presomitic mesoderm
to humans and is perhaps best established as a tool [11] to the pituitary gland [12]. These lines greatly facili-
for small molecule discovery. This review will focus on tate detection of anatomical changes caused by small
studies involving zebrafish, with the recognition that molecules. Fluorescent assays have also been devel-
many of the ideas discussed may be applicable to other oped that report changes in zebrafish physiology. These
assays include a transgenic line in which expression ofmodel organisms as well.
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Figure 2. Zebrafish Attributes Facilitate High-
Throughput Screening
(A) Zebrafish larvae 6 days post fertilization
possess most of the tissues and organs of
the fully developed vertebrate.
(B) Zebrafish embryos fit easily in the wells
of a standard 384-well compound screening
plate.
(C) The visibility of anatomic features can be
increased by tissue-specific expression of
fluorescent proteins. The larva shown ex-
presses green fluorescent protein in the pitu-
itary, driven by the proopiomelanocortin gene
promoter [12] (image courtesy of S. Lin and
N. Liu).
(D and E) Lipid metabolism can be rapidly
assayed using fluorescently quenched phos-
pholipids. Cleavage in vivo is manifest by ac-
cumulation of fluorescent products in the gall
bladder. fat free mutants process the sub-
strate less efficiently, resulting in decreased
fluorescence. (Images in [D] and [E] are re-
printed with permission from [15]. Copyright
2001, American Association for the Advance-
ment of Science.)
green fluorescent protein is induced upon activation of Discovery of Chemical Probes
for Developmental Biologythe aryl hydrocarbon receptor [13, 14]. These lines have
been proposed for use as sentinels for automated detec- Perhaps the most obvious application for zebrafish
chemical screening is the discovery of small moleculetion of fresh water toxicants that activate the aryl hydro-
carbon receptor. Similar lines could be engineered for probes for developmental biology. The zebrafish is well
established as a model organism for developmental biol-high-throughput screening for chemical activators of
any gene of interest. In another assay, lipid metabolism ogy. Forward genetic screens have been successful at
identifying thousands of mutations that affect develop-is measured in vivo based on a fluorescent signal gener-
ated by cleavage of quenched phospholipid substrates ment of nearly every organ system [21, 22]. The screen-
ing methodologies used for identifying zebrafish genetic[15]. Larval zebrafish are fed fluorescently quenched
phospholipids that are cleaved in vivo and transported mutants are readily adapted for chemical screening, and
the collection of mutants provides us with some senseto the gall bladder where they are readily visualized
(Figures 2D and 2E). In short, the transparency of the of the kinds of phenotypes that may be expected.
The simplest screens for chemical modifiers of devel-zebrafish embryo makes it possible to rapidly assess
the effects of small molecules on many aspects of anat- opment involve arraying water and wild-type embryos
into the wells of 96- or 384-well plates, adding smallomy or physiology.
As zebrafish have become more widely used, addi- molecules from a chemical library to the water in the
wells, and allowing development to proceed. At prede-tional technologies have been developed that have in-
creased the utility of the system even further. The zebra- termined stages of development, the embryos are
screened visually for developmental perturbations in thefish genome project is now nearly complete, and DNA
microarrays have been generated for expression profil- system(s) of interest (Figure 3). In one such screen, four
organ systems—the central nervous system, the cardio-ing studies [16, 17]. Cloning of zebrafish by nuclear transfer
has been accomplished [18], and antisense morpholino vascular system, the ear, and the skin—were examined
using a dissecting microscope [23]. After screening 1100oligonucleotides have proven to be an effective means
of “knocking down” gene function [19]. More recently, small molecules, modifiers of all four systems were iden-
tified. One compound called 32N5 causes a malforma-reverse genetic approaches have been developed for
the zebrafish, enabling researchers to generate mutations tion of the hindbrain. Another, 32P6, causes a heart
patterning alteration in which the ventricle forms within,in virtually any gene of interest [20]. Thus, the zebrafish
is rapidly becoming a mature model organism armed with rather than adjacent to, the atrium. Two compounds
affect the development of melanocytes in the skin. Onean impressive collection of genomic and experimental
tools. These tools are also broadening the scope of of these blocks pigment production in all cells by inhib-
iting the enzyme tyrosinase. The other prevents devel-whole-organism chemical screens that can be imagined.
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Figure 3. Screening for Chemical Modifiers
of Vertebrate Development
Adult zebrafish lay hundreds of fertilized eggs
each morning. Embryos are arrayed in assay
plates, and compounds from small molecule
libraries are added to the water in each well.
Embryos are allowed to develop and are
screened visually for developmental defects.
Examples of specific developmental pheno-
types include elongation of the notochord
(A), absence of blood ([B], untreated, upper;
treated, lower), and loss of a single otolith in
the ear (C).
opment of only a subset of pigmented cells that are of structures at various developmental time points [24].
Because genetic mutation is generally permanent, it isderived from the neural crest. Apparently, this com-
pound blocks the specification of neural crest cells to often difficult to distinguish the role of a gene at a later
stage of development from secondary effects of disruptingbecome melanocytes or their subsequent proliferation.
In other screens, small molecules have been identified the gene at earlier stages. In contrast, small molecules
can be added and removed at any stage of development.that block differentiation of blood cells, prevent forma-
tion of the eyes, alter the length of the notochord, or The sonic hedgehog (Shh) pathway is one of the few
developmental pathways for which a specific small mol-affect fin length (unpublished results). Thus, the range
of developmental phenotypes that can be identified by ecule modifier exists. Cyclopamine, which antagonizes
the sonic hedgehog effector smoothened [25], has provensmall molecule screens seems almost limitless.
Several of the compounds discovered by small mole- invaluable for determining the role of the hedgehog
pathway in later developmental events. One recent illus-cule developmental screens appear to be potent and
specific [23]. The molecule 32P6 affects heart chamber tration of this was the use of cyclopamine to determine
how different muscle cell types are specified in the de-patterning with an EC50 of 2 nM. Although less potent,
another molecule (31N3) causes a remarkably specific veloping myotome [26]. During zebrafish myotome de-
velopment, the specification of three muscle cell types—developmental phenotype. Embryos treated with 31N3
fail to form the two tiny otoliths of the inner ear, while the muscle pioneers, the superficial slow fibers, and
medial fast fibers—are all dependent upon Shh. Wolffthe rest of embryo appears to develop normally. The
specificity of the phenotypes identified by chemical et al. elegantly showed that the correct specification
of the proper cell type is a function of both the level ofscreening seems to approach those identified by ge-
netic screens. In fact, several small molecules pheno- hedgehog to which they are exposed and the timing of
the exposure [26]. To do this, they treated embryos withcopy specific genetic mutations.
Given that thousands of developmental mutants have cyclopamine at various times and concentrations and
demonstrated that the cell identities of the myotomealready been identified, what additional value will be
added by identifying chemical modifiers of develop- are altered by the resulting changes in the timing and
strength of hedgehog signaling. Such an analysis wouldment? Having temporal control over disruption of devel-
opmental pathways is one significant benefit, especially not have been possible without the temporal and quanti-
tative control offered by the small molecule cyclopam-since development is inherently such a time-dependent
process. Signaling pathways involved in early develop- ine. It is probable that small molecules discovered by
whole-organism screening in zebrafish will, like cyclo-ment often perform additional roles at later stages of
development. The sonic hedgehog pathway, for exam- pamine, be useful tools for dissecting other aspects of
vertebrate development. One such molecule has alreadyple, is believed to be involved in development of dozens
Review
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been useful for studying the mechanism of determining Success has also been achieved generating zebrafish
models of infection, and there may be advantages toheart chamber orientation during development [27].
One major obstacle that may limit the utility of small screening for antimicrobial compounds in the context
of a whole organism. Some infectious pathogens cannotmolecule developmental screens is the current difficulty
of identifying molecular targets for novel compounds. be cultured outside of a host, and a zebrafish model
may allow these pathogens to be subjected to high-Once a small molecule is identified that disrupts a devel-
opmental process of interest, no systematic process throughput chemical screening. Furthermore, screening for
antimicrobials in an organismal context would allow se-exists for identifying the responsible target. Several ap-
proaches to small molecule target identification have lection of compounds with activity against the microbe
but without undue toxicity to the host.proven successful in the past, including candidate gene
approaches, expression cloning, and affinity chroma- Two recent papers highlight the potential of zebrafish
for modeling infectious diseases. Davis et al. demon-tography using immobilized small molecules [28]. How-
ever, not every approach works in every situation, and strated that zebrafish embryos can be readily infected
with Mycobacterium marinum, a close relative of theselection of the appropriate approach often requires trial
and error. If a systematic, reliable means of identifying agent that causes tuberculosis in humans, Mycobacte-
rium tuberculosis [35]. In zebrafish, the mycobacteriasmall molecule targets can be developed, the ability of
developmental biology to benefit from the discovery of cause chronic infection of macrophages and result in
formation of tuberculous granulomas exhibiting manychemical probes will be greatly enhanced. Several meth-
ods for systematizing target identification have been of the hallmarks of tuberculosis. Granuloma-specific
mycobacterium genes are also activated, and the infec-proposed, including synthesis of chemical libraries with
preattached linkers. One such library was used to iden- tion reliably results in death of the zebrafish by 9 days
post infection. Mycobacteria engineered to expressestify a small molecule that affects zebrafish brain devel-
opment [29]. The preattached linker allowed facile gen- green fluorescent protein were used, making it easy to
observe progression of the infection. Van Der Sar eteration of an affinity matrix and biochemical purification
of a protein binding partner. al. performed similar experiments using DsRed-labeled
Salmonella typhimurium and demonstrated that infec-
tion progresses much as in established murine modelsZebrafish Screens for Drug Discovery
Beyond discovery of small molecule probes for funda- [36]. The bacterium multiplies in macrophages and at
blood vessel epithelial cells and is ultimately lethal. Inmental biological research, it may be possible to use
zebrafish screens to identify lead compounds with ther- both examples, it is easy to envision high-throughput
screening for compounds that prevent progression ofapeutic potential. If human diseases can be accurately
modeled in zebrafish, chemical screens using zebrafish the infection, either by observing the fluorescently la-
beled pathogen directly or by selecting compounds thatdisease models as substrates could be used to identify
compounds that ameliorate the disease phenotypes. permit survival of the zebrafish host beyond the time of
expected lethality.Importantly, even diseases without a known, druggable
target may be amenable to this approach, because no One question that remains to be answered is whether
small molecules that modify a disease phenotype inprior assumptions about the mechanism of disease
amelioration are necessary. zebrafish will have similar activity in humans. That ques-
tion has not been answered, but it has been shownMany diverse zebrafish disease models have already
been developed and are reviewed elsewhere [30–32]. that several drugs with known effects in humans cause
analogous effects in zebrafish. In one study, Milan et al.Most of these models fit within one of three categories.
In the first, the human disease and the zebrafish model exposed zebrafish to 23 drugs known to lengthen a
portion of the cardiac cycle in humans known as theshare the same phenotypic manifestation and are known
to share the same underlying cause. For example, hu- QT interval [37]. Of the 23 drugs, 22 also caused an
analogous prolongation of the cardiac cycle in zebrafish.mans with hereditary hemorrhagic telangiectasia and
zebrafish violet beauregarde mutants both have arterio- Other drugs with similar activities in fish and humans
include cholesterol synthesis blockers, vasodilators, an-venous malformations and share mutations in the activin
receptor-like kinase 1 gene [33]. Disease models in this giogenesis inhibitors, and anticoagulants, as reviewed
elsewhere [38]. Therefore, it appears that drug bindingcategory are obvious candidates for zebrafish-based
sites are generally well conserved between humans anddrug lead discovery. In the second category, human and
zebrafish, and many compounds that are active in zebra-fish share similar disease phenotypes but are not known
fish may have similar activities in humans. This fact com-to share the same underlying cause. The zebrafish grid-
bined with the existence of good zebrafish disease mod-lock mutation, for example, causes a malformation of
els suggests that zebrafish-based screening for newthe aorta that is similar in many ways to coarctation of
drug leads may be possible. Several such screens arethe aorta in humans [34]. However, because the cause
currently underway.of coarctation of the aorta in humans is not known, it is
unclear whether the underlying defect in humans and
fish is the same. In the final category, human and zebra- High-Content Characterization
of Chemical Librariesfish share the same genetic defect but exhibit different
phenotypic manifestations. Even models falling within In addition to their use for small molecule screening
itself, zebrafish assays can play supporting roles in thethis third category may be amenable to zebrafish small
molecule screens, because small molecules that modify process of small molecule discovery. Because zebrafish
assays are “high-content” assays, a single embryo canthe surrogate zebrafish phenotype may be effective at
modifying the real phenotype in humans. provide a great deal of information about the molecule
Chemistry & Biology
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Figure 4. High-Throughput Assays of Car-
diovascular Physiology
(A) Automated video microscopy captures
15 s videos of zebrafish hearts in 96- or 384-
well plates. Data from one 384-well plate can
be acquired in less than 2 hr. Light intensity
in the region of the heart is plotted as a func-
tion of time.
(B) Computer algorithms automatically ex-
tract physiological data from the videos, in-
cluding heart rate.
(C) High-throughput screens can be used to
detect individual compounds or combina-
tions that affect cardiovascular physiology
[37]. In this example, a QT prolonging interac-
tion between erythromycin and cisapride was
detected. Atrial rate is plotted against in-
creasing doses of cisapride. Erythromycin
concentrations are indicated in the inset.
Erythromycin and cisapride alone have little
effect on heart rate, but together they cause
severe bradycardia. (Images courtesy of Da-
vid Milan.)
to which it is exposed. As such, zebrafish assays are prolongation [37]. With few exceptions, individual drugs
and drug combinations that cause QT prolongation inexcellent for characterizing collections of compounds
at various stages in the compound discovery process. humans also cause bradycardia in zebrafish and can be
detected by the automated zebrafish assay (Figure 4).This characterization can take the form of testing librar-
ies for functional diversity and biological activity. Par- As with most emerging technologies, more experimen-
tation and practical application will have to be performedticularly after synthesis of novel chemical libraries via
combinatorial chemistry, it is important to gauge the before the real utility of zebrafish toxicity screening can
be determined. However, the ability to perform whole-likelihood that the libraries contain compounds with bio-
logical activity. Because disrupting any one of thou- animal studies rapidly, inexpensively, and in large num-
bers is an appealing possibility.sands of gene products in the zebrafish causes an ob-
servable phenotype, testing even a relatively small number
of library compounds is often sufficient to assess a li- Conclusions
In vitro, nonorganismal screens are likely to remain abrary’s potential for biological activity. Zebrafish devel-
opmental assays have been used in this way for prelimi- mainstay of small molecule discovery efforts, particu-
larly those directed at well-understood biological pro-nary characterization of several novel combinatorial
libraries [39–41]. cesses. However, organism-based screens address
some of the shortcomings of modern small moleculeDuring drug discovery and development, early detec-
tion of compounds that cause unacceptable toxicity can discovery, notably the lack of appropriate physiological
context provided by in vitro assays and the difficulty ofsave much wasted time and expense. Inexpensive, high-
throughput zebrafish toxicity assays can be used to approaching biological problems for which previously
validated targets do not exist. Drug discovery effortseliminate toxic compounds before time and money are
invested in their further development. This can occur may benefit from the increased efficiency of combining
screening and animal tests into one step. Zebrafishprior to screening by testing whole libraries or after
screening as a means of prioritizing hits for further devel- screens may also impact drug discovery by allowing
diseases to be tackled that were previously intractableopment. The zebrafish is becoming a well-accepted
model for toxicologic pathology [42], and at least one by target-based methods.
At present, small molecule discovery is largely thecompany has been founded with the intent to provide
zebrafish screening services for drug toxicity profiling. purview of the pharmaceutical industry. Perhaps the
most significant contribution of organism-based screen-High-throughput assays for specific types of toxicity
have also been developed. For example, prolongation ing will be in helping to increase the feasibility and ap-
peal of performing small molecule discovery in aca-of the QT interval is a common culprit behind abandon-
ment of previously promising drug leads. Milan et al. demic settings. Far from requiring the equipment and
automation of a high-throughput screening facility, anydeveloped an automated system for measuring zebra-
fish heart rate data in 96- and 384-well plates and lab with a few fish tanks, a chemical library, and a micro-
scope can perform a zebrafish chemical screen. Andshowed that the system can be used to predict QT
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